HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

  • STATUS
    Recruiting
  • End date
    Jul 19, 2024
  • participants needed
    420
  • sponsor
    Daiichi Sankyo, Inc.
Updated on 19 July 2021

Summary

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

Description

This study will initially randomize participants to one of 2 arms in a 1:1 ratio to receive either a 5.6 mg/kg fixed dose regimen or an up-titration dose regimen of patritumab deruxtecan (HER3-DXd, U3-1402).

Details
Condition Non Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Treatment Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Clinical Study IdentifierNCT04619004
SponsorDaiichi Sankyo, Inc.
Last Modified on19 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for
inclusion in this study
Sign and date the tissue informed consent form (ICF) and the main ICF, prior to the start of any study-specific qualification procedures
Male or female participants aged 18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old)
Histologically or cytologically documented locally advanced or metastatic NSCLC not amenable to curative surgery or radiation
Documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease. Participants must have received both of the following
Prior treatment with osimertinib. Participants receiving an EGFR TKI at the time of signing informed consent should continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1. Participants in South Korea known to harbor a clinically actionable genomic alteration in addition to EGFR mutation (e.g., anaplastic lymphoma kinase [ALK] or ROS1 protocol oncogene 1 [ROS1] fusion) for which treatment is available must have also received prior treatment with at least 1 approved genotype-directed therapy, unless unable (i.e., if contraindicated). No new testing for these genomic alterations (e.g., ALK or ROS1 fusion) is required for Screening
Systemic therapy with at least 1 platinum-based chemotherapy regimen
Documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R
At least 1 measurable lesion confirmed by BICR as per RECIST v1.1
Consented and willing to provide required tumor tissue of sufficient quantity and of adequate tumor tissue content. Required tumor tissue can be provided as either
Pretreatment tumor biopsy from at least 1 lesion not previously irradiated and amenable to core biopsy OR
Archival tumor tissue collected from a biopsy performed within 3 months prior to signing of the tissue consent and since progression while on or after treatment with the most recent cancer therapy regimen
Eastern Cooperative Oncology Group Performance Standard of 0 or 1 at Screening
Has adequate bone marrow reserve and organ function based on local laboratory data within 14 days prior to Cycle 1 Day 1
Platelet count : 100,000/mm^3 or 100 10^9/L (platelet transfusions are not allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)
Hemoglobin: 9.0 g/dL (transfusion and/or growth factor support is allowed)
Absolute neutrophil count: 1500/mm^3 or 1.5 10^9/L
Serum creatinine (SCr) or creatinine clearance (CrCl): SCr 1.5 upper limit of normal (ULN), OR CrCl 30 mL/min as calculated using the Cockcroft-Gault equation or measured CrCl
Aspartate aminotransferase/alanine aminotransferase: 3 ULN (if liver metastases are present, 5 ULN)
Total bilirubin: 1.5 ULN if no liver metastases (<3 ULN in the presence of documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases)
Serum albumin: 2.5 g/dL
Prothrombin time (PT) or PT-International normalized ratio (INR) and activated partial thromboplastin time (aPTT)/PTT: 1.5 ULN, except for subjects on coumarin-derivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator

Exclusion Criteria

Participants meeting any exclusion criteria for this study will be excluded
from this study
Any previous histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the archival tumor tissue or pretreatment tumor biopsy
Any history of interstitial lung disease (including pulmonary fibrosis or radiation pneumonitis), has current interstitial lung disease (ILD), or is suspected to have such disease by imaging during screening
Clinically severe respiratory compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to
Any underlying pulmonary disorder (eg, pulmonary emboli within 3 months prior to the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD]), restrictive lung disease, pleural effusion)
Any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis); OR prior complete pneumonectomy
Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory or any form of immunosuppressive therapy prior to enrollment. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study
Evidence of any leptomeningeal disease
Evidence of clinically active spinal cord compression or brain metastases
Inadequate washout period prior to Cycle 1 Day 1, defined as
Whole brain radiation therapy <14 days or stereotactic brain radiation therapy <7 days
Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI), <14 days or 5 half-lives, whichever is longer
Monoclonal antibodies, other than immune checkpoint inhibitors, such as bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) <28 days
Immune checkpoint inhibitor therapy <21 days
Major surgery (excluding placement of vascular access) <28 days
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation <28 days or palliative radiation therapy <14 days; or
Chloroquine or hydroxychloroquine <14 days
Prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody or single-agent topoisomerase I inhibitor
Prior treatment with an antibody drug conjugate (ADC) that consists of any topoisomerase I inhibitor
Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, Grade 1 or baseline. Participants with chronic Grade 2 toxicities may be eligible at the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee
Has history of other active malignancy within 3 years prior to enrollment, except
Adequately treated non-melanoma skin cancer
Superficial bladder tumors (Ta, Tis, T1)
Adequately treated intraepithelial carcinoma of the cervix uteri
Low risk non-metastatic prostate cancer (with Gleason score <7, and following local treatment or ongoing active surveillance)
Any other curatively treated in situ disease
Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1
Active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1
Participant with any human immunodeficiency virus (HIV) infection
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note